Altrius Capital Management Inc Increases Stock Position in Pfizer Inc. (NYSE:PFE)

Altrius Capital Management Inc raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 35.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 132,016 shares of the biopharmaceutical company’s stock after purchasing an additional 34,783 shares during the period. Altrius Capital Management Inc’s holdings in Pfizer were worth $3,801,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Briaud Financial Planning Inc acquired a new position in Pfizer during the third quarter worth about $30,000. Mizuho Securities Co. Ltd. purchased a new stake in shares of Pfizer in the 3rd quarter valued at approximately $34,000. VisionPoint Advisory Group LLC raised its stake in shares of Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares during the period. GoalVest Advisory LLC raised its stake in shares of Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 811 shares during the period. Finally, Tennessee Valley Asset Management Partners purchased a new stake in Pfizer during the 4th quarter worth approximately $36,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on PFE. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research note on Thursday, January 4th. Guggenheim assumed coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Eleven analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus target price of $36.33.

Pfizer Stock Up 0.9 %

Shares of Pfizer stock traded up $0.24 during trading hours on Monday, hitting $25.64. The company had a trading volume of 39,998,605 shares, compared to its average volume of 41,992,512. The company’s 50-day moving average is $26.96 and its two-hundred day moving average is $28.36. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $40.37. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The company has a market cap of $145.19 billion, a P/E ratio of 71.03, a price-to-earnings-growth ratio of 1.14 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. Pfizer’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.14 EPS. Analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be given a dividend of $0.42 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 6.55%. Pfizer’s payout ratio is currently 466.67%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.